These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 24322983

  • 1. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
    Cheng H, Liu P, Zhang F, Xu E, Symonds L, Ohlson CE, Bronson RT, Maira SM, Di Tomaso E, Li J, Myers AP, Cantley LC, Mills GB, Zhao JJ.
    Cancer Res; 2014 Jan 01; 74(1):15-23. PubMed ID: 24322983
    [Abstract] [Full Text] [Related]

  • 2. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.
    PLoS One; 2012 Jan 01; 7(5):e37431. PubMed ID: 22662154
    [Abstract] [Full Text] [Related]

  • 3. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.
    Contreras CM, Akbay EA, Gallardo TD, Haynie JM, Sharma S, Tagao O, Bardeesy N, Takahashi M, Settleman J, Wong KK, Castrillon DH.
    Dis Model Mech; 2010 Jan 01; 3(3-4):181-93. PubMed ID: 20142330
    [Abstract] [Full Text] [Related]

  • 4. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
    Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, Broaddus RR, Walker CL.
    Clin Cancer Res; 2008 May 01; 14(9):2543-50. PubMed ID: 18451215
    [Abstract] [Full Text] [Related]

  • 5. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X, Gao J, Luo F, Rui C, Zheng T, Wang D, Wang Y, Roberts TM, Liu P, Zhao JJ, Cheng H.
    Oncogene; 2018 Jan 18; 37(3):341-351. PubMed ID: 28945226
    [Abstract] [Full Text] [Related]

  • 6. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T, Yamada T, Koenig MJ, Xu J, Okimoto T, Li F, Amann JM, Carbone DP.
    J Thorac Oncol; 2019 Jun 18; 14(6):1061-1076. PubMed ID: 30825612
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH, Yasmeen A.
    BMC Cancer; 2017 Sep 08; 17(1):638. PubMed ID: 28886696
    [Abstract] [Full Text] [Related]

  • 8. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1.
    Tanwar PS, Kaneko-Tarui T, Zhang L, Tanaka Y, Crum CP, Teixeira JM.
    PLoS Genet; 2012 Sep 08; 8(8):e1002906. PubMed ID: 22916036
    [Abstract] [Full Text] [Related]

  • 9. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
    Korets SB, Musa F, Curtin J, Blank SV, Schneider RJ.
    Gynecol Oncol; 2014 Feb 08; 132(2):468-73. PubMed ID: 24316308
    [Abstract] [Full Text] [Related]

  • 10. AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.
    Liu JL, Mao Z, Gallick GE, Yung WK.
    Neuro Oncol; 2011 Feb 08; 13(2):184-94. PubMed ID: 21123367
    [Abstract] [Full Text] [Related]

  • 11. Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice.
    Bajwa P, Nielsen S, Lombard JM, Rassam L, Nahar P, Rueda BR, Wilkinson JE, Miller RA, Tanwar PS.
    Oncotarget; 2017 Jan 31; 8(5):7265-7275. PubMed ID: 27980219
    [Abstract] [Full Text] [Related]

  • 12. Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice.
    García-Martínez JM, Wullschleger S, Preston G, Guichard S, Fleming S, Alessi DR, Duce SL.
    Br J Cancer; 2011 Mar 29; 104(7):1116-25. PubMed ID: 21407213
    [Abstract] [Full Text] [Related]

  • 13. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
    Kinross KM, Brown DV, Kleinschmidt M, Jackson S, Christensen J, Cullinane C, Hicks RJ, Johnstone RW, McArthur GA.
    Mol Cancer Ther; 2011 Aug 29; 10(8):1440-9. PubMed ID: 21632463
    [Abstract] [Full Text] [Related]

  • 14. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice.
    Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, McBurnie W, Fleming S, Alessi DR.
    Biochem J; 2008 Jun 01; 412(2):211-21. PubMed ID: 18387000
    [Abstract] [Full Text] [Related]

  • 15. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
    Xiao P, Sun LL, Wang J, Han RL, Ma Q, Zhong DS.
    Acta Pharmacol Sin; 2015 Sep 01; 36(9):1107-12. PubMed ID: 26027660
    [Abstract] [Full Text] [Related]

  • 16. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes PTEN & LKB1 in human uterine leiomyomas.
    Makker A, Goel MM, Mahdi AA, Bhatia V, Das V, Agarwal A, Pandey A.
    Indian J Med Res; 2016 May 01; 143(Supplement):S112-S119. PubMed ID: 27748285
    [Abstract] [Full Text] [Related]

  • 17. Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status.
    Fong P, Meng LR.
    Med Sci Monit Basic Res; 2014 Sep 30; 20():146-52. PubMed ID: 25266877
    [Abstract] [Full Text] [Related]

  • 18. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
    Bradford LS, Rauh-Hain A, Clark RM, Groeneweg JW, Zhang L, Borger D, Zukerberg LR, Growdon WB, Foster R, Rueda BR.
    Gynecol Oncol; 2014 May 30; 133(2):346-52. PubMed ID: 24561032
    [Abstract] [Full Text] [Related]

  • 19. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F.
    Gynecol Oncol; 2015 Jul 30; 138(1):165-73. PubMed ID: 25933683
    [Abstract] [Full Text] [Related]

  • 20. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
    Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O.
    Br J Cancer; 2013 Sep 17; 109(6):1586-92. PubMed ID: 23989949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.